<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343001</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KEP-420</org_study_id>
    <nct_id>NCT04343001</nct_id>
  </id_info>
  <brief_title>Coronavirus Response - Active Support for Hospitalised Covid-19 Patients</brief_title>
  <acronym>CRASH-19</acronym>
  <official_title>Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults
      hospitalised with suspected or confirmed acute COVID-19 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will evaluate the effect of aspirin (150mg once daily), losartan (100mg once daily), and
      simvastatin (80mg once daily) in patients with COVID-19 infection.

      Eligible patients will be randomly allocated to one of eight study arms (aspirin only;
      losartan only; simvastatin only; aspirin and losartan; aspirin and simvastatin; losartan and
      simvastatin; aspirin, losartan and simvastatin; standard care only). Trial treatments are
      given in addition to the usual standard of care at the study hospital.

      Treatment will be started as soon as possible after randomisation and will continue until
      death, discharge or 28 days after randomisation, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2 x 2 x 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
    <description>Cause of death will be described</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congestive cardiac failure</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe cardiac arrythmia</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocarditis</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory failure including ARDS</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral pneumonitis</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal bleeding</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt of non invasive or mechanical ventilation</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to self care at hospital discharge</measure>
    <time_frame>up to 28 days of randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual standard of care at the study hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 150mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 80mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin and Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin and Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 150mg once daily and Simvastatin 80mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan and Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin, Losartan and Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 150mg</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Aspirin and Losartan</arm_group_label>
    <arm_group_label>Aspirin and Simvastatin</arm_group_label>
    <arm_group_label>Aspirin, Losartan and Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 100mg</description>
    <arm_group_label>Aspirin and Losartan</arm_group_label>
    <arm_group_label>Aspirin, Losartan and Simvastatin</arm_group_label>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_label>Losartan and Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 80mg</description>
    <arm_group_label>Aspirin and Simvastatin</arm_group_label>
    <arm_group_label>Aspirin, Losartan and Simvastatin</arm_group_label>
    <arm_group_label>Losartan and Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 40 years and older

          -  with suspected or confirmed acute COVID-19 infection. Acute COVID-19 infection is
             suspected in the presence of a fever and at least one symptom of respiratory disease
             e.g. cough, difficulty breathing, signs of hypoxia. The clinician may suspect COVID-19
             infection if i) the patient lives in or has recently travelled to an area with
             COVID-19 transmission; ii) the patient had recent contact with a confirmed or probable
             COVID-19 case, or iii) no alternative diagnosis fully explains the clinical
             presentation

          -  requiring hospitalisation

        Exclusion Criteria:

          -  Women known to be pregnant

          -  Patients hospitalised without symptoms of acute COVID-19 infection should not be
             recruited even if they test positive for COVID-19

          -  Patients already receiving mechanical ventilation

          -  Patients with a definite indication or contraindication for any of the trial
             treatments.

          -  Patients who are very severely frail (completely dependent and approaching end of life
             who typically they could not recover even from a mild illness) or terminally ill
             should not be recruited.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur-Still</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Roberts</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haleema Shakur-Still</last_name>
    <phone>+44 207 958 8113</phone>
    <email>haleema.shakur-still@lshtm.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ian Roberts</last_name>
    <phone>+44 207 958 8128</phone>
    <email>ian.roberts@lshtm.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <state>Oyo</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <contact>
      <last_name>Temitayo Shokunbi</last_name>
    </contact>
    <investigator>
      <last_name>Nike Bello</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oladapo Olayemi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shifa Tameer-e-Millat University</name>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <contact>
      <last_name>Rizwana Chaudhri</last_name>
    </contact>
    <investigator>
      <last_name>Aasia Kayani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiran Javaid</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Nigeria</country>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Respiratory Distress Syndrome</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Myocardial infarction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As many sites will contribute to this trial, individual sites cannot restrict the publication of the manuscript relating to the outcomes of this trial. All anonymised data from this trial will be made freely available on our data sharing site: http://freebird.lshtm.ac.uk.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within 6 months or sooner of publication</ipd_time_frame>
    <ipd_access_criteria>Log-in required for the sole purpose to monitor data download.</ipd_access_criteria>
    <ipd_url>http://freebird.lshtm.ac.uk</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

